Global Triple Negative Breast Cancer Market – Industry Trends and Forecast to 2030

Triple Negative Breast Cancer Market Analysis and Size

Breast cancer is the second most prevalent cancer in the world and is the most common cancer in women worldwide. Mostly metastatic breast cancer may be detected months or years after the advanced or early detection and treatment of breast cancer, such as stages 1, 2, or 3. Current advancements in cancer research continue to lead to the launch of newer and better treatment options, including drug therapies. The endlessly improving healthcare infrastructure, combined with the surge in people's disposable incomes, is expected to make the market grow in the forecast period.

Data Bridge Market Research analyses a growth rate in the global triple negative breast cancer market in 2023-2030. The expected CAGR of the global triple negative breast cancer market is around 5.50% in the mentioned forecast period. The market was valued at USD 953.8 million in 2022 and would grow to USD 1,463.82 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Triple Negative Breast Cancer Market Scope and Segmentation

Market Definition

Triple-negative breast cancer is a type of breast cancer that lacks estrogen receptors, progesterone receptors, and excess human epidermal growth factor receptors (HER2), making hormone therapy ineffective. TNBC differs from other types of breast cancer in that it tends to grow and spread faster and has a worse prognosis. This cancer type has fewer treatment options than others as the cancer cells do not have the estrogen, progesterone receptors, or HER2 protein to make hormone therapy or targeted HER2 drugs work.

Global Triple Negative Breast Cancer Market Dynamics

Drivers

• Rise in Breast Cancer Cases

As per breastcancer.org, in 2023, it is estimated that nearly 30% of the newly discovered cancer cases in women get diagnosed with breast cancer. Furthermore, triple-negative breast cancer (TNBC) accounts for around 10-15% of all breast cancers. Furthermore, the extensive R&D activities to achieve successful therapeutic for this disease and the increasing number of patients with breast cancer are enhancing the market growth.

• Wide Availability of Biosimilar and Generic Anti-Cancer Drugs

The increasing availability of biosimilar and affordable generic anti-cancer drugs in developing nations is anticipated to decrease the burden of cancer care significantly. An estimated cost reduction of around 30% – 40% and extended use of generic drugs is anticipated to decrease overall cancer treatment costs, thus increasing the treatment rate for triple-negative breast cancer. Thus, this boosts market growth.

Opportunities

• Increasing Demand for Hospitals

The growing number of hospitals in highly developing nations and the wide availability of numerous medical treatment equipment and drugs led to the high market size development. As per AHRQ, there were around 2.8 million cancer-related adult nonmaternal hospitalizations. Among these cases, about 1.0 million stays had cancer patients, comprising a total cost of about USD 23.0 billion, accounting for 6.2 % of the total adult nonmaternal inpatient hospital costs. Thus, this huge demand is creating many opportunities for market growth.

• Higher Adoption of Immunotherapy

The segment of immunotherapy is expected to gain attraction during the forecast period. Immunotherapeutics tend to have fewer adverse effects than other chemotherapeutics. Non-specificity, toxic side effects, and the huge development of resistance associated with chemotherapy are most likely to decrease the growth of chemotherapeutics and increase the adoption of immunotherapeutics and other targeted treatments. This creates more opportunities in the market.

Restraints/Challenges

• Lack of Skilled Professionals

A lack of trained professionals unaware of the appropriate treatment methods for this triple negative breast cancer could restrain the market's growth. Cancer needs specialized treatments as each type is different, and not all professionals are aware of the detailing of the cancer type and its associated treatment. Thus, this factor impedes market growth.

This global triple negative breast cancer market  report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global triple negative breast cancer market  contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments:

• In 2020, Roche collaborated with Kenya's government to improve breast cancer treatment. This campaign was launched to increase women's access to breast cancer prevention and treatment services.
• In 2021, sacituzumab govitecan successfully received FDA approval for treating metastatic triple-negative breast cancer patients who had already undergone two or more systemic treatments before, out of which at least one was for metastatic illness.

Global Triple Negative Breast Cancer Market Scope

The global triple negative breast cancer market  is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Immunotherapy
• Targeted Therapy
• Chemotherapy
• Hormone Therapy
• Others

Route of Administration

• Oral
• Parenteral

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Triple Negative Breast Cancer Market Regional Analysis/Insights

The global triple negative breast cancer market  is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global triple negative breast cancer market  report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to the increasing cases of HER2-positive breast cancer and favorable government policies and advanced healthcare facilities. Additionally, the continuous research and development activities by major market players will further boost the growth of the region's triple negative breast cancer market during the forecast period.

Asia-Pacific is projected to grow significantly because of increased government initiatives and rapidly growing disposable income. In contrast, the growing product launches and developments associated with this disease further boost regional growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Triple Negative Breast Cancer Market Share Analysis

The global triple negative breast cancer market  competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global triple negative breast cancer market.

Key players operating in the global triple negative breast cancer market include:

• Johnson & Johnson Private Limited (U.S.)
• Cipla Inc. (U.S.)
• Abbott (U.S.)
• AbbVie Inc. (U.S.)
• Merck KGaA (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Amneal Pharmaceuticals LLC. (U.S.)
• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Bristol-Myers Squibb Company (U.S.)
• GSK plc. (U.K.)
• Bayer AG (Germany)

SKU-54305